Sign in Sign up for free

Albireo Pharma Inc Institutional ownership

What is the Institutional ownership of Albireo Pharma Inc?

The Institutional ownership of Albireo Pharma Inc is 100.00%

What is the definition of Institutional ownership?



Institutional Ownership is the amount of a company’s available stock owned by mutual or pension funds, insurance companies, investment firms, endowments or other large entities that manage funds on the behalf of others.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Institutional ownership of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc

What does Albireo Pharma Inc do?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Companies with institutional ownership similar to Albireo Pharma Inc